Clinical Effects Observation Of Longmu Anshen Dingxian Granules Combined With Etiracetam In Patients With Post Stroke Epilepsy,Phlegm-Blood Stasis Type

Objective:To investigate the clinical efficacy of Longmu Anshen Dingxian granules for patients with post-stroke epilepsy(phlegm-blood stasis type),through a clinical pilot study,in the hope of discovering the therapeutic effect of Longmu Anshen Dingxian granules.Methods:In this study,random grouping of patients was selected,and the research method of controlled observation was used to screen patients with post-stroke epilepsy(phlegm-blood stasis type)with mixed phlegm and blood stasis who visited Cangzhou Hospital of Integrated Traditional Chinese and Western Medicine in Hebei Province from November 2021 to October 2022.80 patients who met the criteria of this study were screened out.Randomly divided into control group(40 cases)and observation group(40 cases).The control group was given routine basic treatment of cerebral and western medicinesuch as antihypertensive,hypolipidemic,anti-inflammatory,neurotrophic,anticoagulant,antiplatelet aggregation,and microcirculation stabilization,and western medicine levetiracetam anti-epileptic treatment.The observation group was treated with the basic treatment and the western medicine levetiracetam,plus the traditional Chinese medicine experience prescription Longmu Anshen Dingxian granules(drugs from Hebei Cangzhou Hospital of Integrated Chinese and Western Medicine).All the selected patients were strictly observed and recorded the National Institutes of Health Stroke Scale(NIHSS)score and TCM syndrome score of the two groups of patients before and after treatment,and compared the two groups Patients in group epileptic seizures during treatment,and the effective rate of epilepsy control in the two groups was assessed;The serum levels of inflammatory factor interleukin-8(1L-8),tumor necrosis factorA(TNFra)and neuron-specific enolase(NSE)before and after treatment were compared between the two groups.The results showed as follows:(1)The overall clinical epilepsy control efficiency of the observation group was significantly better than that of the control group(P<0.05);(2)Before treatment,patients in the observation group and the control group were roughly consistent in the NIHSS scale score,after treatmentthere were significant differences in the indicators of patients in the two groups,the indicators of the observation group were significantly better than those in the control group(P<0.05),the difference was comparable;(3)The levels of serum inflammatory factors and NSE were roughly consistent between the observation group and the control group.After treatment,the indexes of the two groups were significantly differentand the indexes of the observation group were significantly better than those of the control group(P<0.05);(4)The TCM syndrome score and the comparative analysis of TCM syndrome efficacy showed that the control group was significantly better than the observation group,the difference was statistically significant(P<0.05);Conclusion:① Longmu Anshen Dingxian granules combined with levetiracetam in the treatment of phlegm-stasis internode type epilepsy after stroke can improve the clinical symptoms of patients and effectively reduce the number of seizures.Reduce the levels of inflammatory factors and NSE,reduce inflammatory response,and protect the blood-brain barrier.②Longmu Anshen Dingxian granules combined with levetiracetam in the treatment of phlegm-stasis internode type epilepsy after stroke have no obvious adverse reactions and toxic side effects.It is suggested that Longmu Anshen Dingxian granules combined with levetiracetam have a significant clinical effect,safe and reliable,it is worth while to use in clinical practice.